NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









KaloCyte, Inc.

KaloCyte, Inc.

Private
Baltimore, MarylandHealthcare & Life Scienceshttps://kalocyte.com/

Last Round

Seed

Feb 24, 2025

Total Funding Raised

$24.13M

Company Overview

KaloCyte, Inc. is a biotechnology company developing ErythroMer™, a dried, bio-inspired artificial red blood cell substitute for use when stored red blood cells are unavailable.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

artificial bloodblood substitutesynthetic bloodoxygen carriernanoparticle encapsulationtrauma careemergency medicineshelf-stable bloodbiosynthetic hemoglobinbattlefield medicinefreeze-dried bloodcombat casualty carepre-hospital carebiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

KaloCyte, Inc. Comparables

Compare KaloCyte, Inc. with similar companies based on industry and business-model similarity.

KaloCyte, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
VirTech Bio
85%
NanoBlood LLC
85%
Fluoro2 Therapeutics
82%

KaloCyte, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedFeb 24, 2025
GrantFeb 1, 2025
GrantJan 28, 2025
GrantApr 15, 2024
GrantAug 22, 2023
Debt
Jul 17, 2023

Key People

Founding team and executive leadership

Elaine Haynes

President And CEO, Board Director

Executive Team

Akunna Iheanacho

Fractional Chief Operating Officer

Executive Team

KaloCyte, Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 24, 2025

    $2.6M round led by Ferocity Capital

  • Jan 28, 2025

    Selected to join collaboration with Johnson & Johnson and BARDA.

KaloCyte, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

KaloCyte, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about KaloCyte, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersBaltimore, Maryland
Employee Range23
Year Founded2016
Last FundingFeb 24, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.